Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
advance till payday
Popular Articles
Teeth Whitening

Niall Dickson To Join The GMC As New Chief Executive
The GMC has appointed Niall Dickson as the new Chief Executive of the General Medical Council. He will take up his post in January next year.
generic viagra online
Lance Armstrong Foundation And American Cancer Society Announce International Partnership To Fight Global Cancer Burden
Today the Lance Armstrong Foundation and the American Cancer Society announced they have formed a first-of-its-kind partnership to empower and support survivors all over the world and aggressively address the global cancer burden. As part of its ongoing global commitment to fight cancer, the Society has become an international collaborating partner for the LIVESTRONG® Global Cancer Summit in Dublin, Ireland in August. The Society will actively participate in LIVESTRONG Global Cancer Campaign events at both the Tour de France in July and the Summit, beginning Aug. 24 in Dublin. John R. Seffrin, Ph.D., chief executive officer, American Cancer Society, will join the U.S. delegation to the Summit and address the 250 advocates selected from all over the world for their commitments to cancer control.
News of the day
ImmunoGen Announces Encouraging New Clinical Data With The Company's IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging initial efficacy, safety and tolerability clinical data with its IMGN901 product candidate in the treatment of small-cell lung cancer (SCLC). In two early-stage clinical trials that enrolled patients whose SCLC had recurred following treatment with standard chemotherapies, IMGN901 administration achieved notable tumor shrinkage and/or sustained stable disease. The compound also demonstrated encouraging activity against other CD56-expressing (CD56+) solid tumors. These clinical data are being presented at the 13th World Conference on Lung Cancer taking place in San Francisco, CA, from July 31 to Aug. 4, 2009.
Cardiovascular

Stem Cell Therapeutics Corp. Announces Publication Of Phase I Stroke Data

Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:SSS) is pleased to announce the acceptance and publication of the paper entitled "Open labeled, uncontrolled pharmacokinetic study of single intramuscular hCG dose in healthy male volunteers" by the International Journal of Clinical Pharmacology and Therapeutics, Vol. 47, August 2009. This paper was authored by Drs. Alan Moore, President & CEO, Allen Davidoff, VP Product Development and Yan Yang, Clinical Research Associate, all of SCT; Dr. Michael D. Hill of Foothills Hospital at the University of Calgary, and Dr. Steven C. Cramer, from the University of California, Irvine. Dr. Allen Davidoff, VP of Product Development, commented as follows: "Acceptance by this highly respected, peer reviewed journal not only permits us to share more of our knowledge of hCG"s novel effects with the scientific community but it is also a meaningful developmental step for NTx®-265. Importantly, this study demonstrated for the first time that hCG circulating in the blood crosses the blood brain barrier leading to concentrations of hCG in the cerebral-spinal fluid. This fundamental evidence, combined with strong supportive basic science studies, supported initiation of the BETAS Phase IIa clinical trial in patients with acute ischemic stroke." This study was designed to compare blood and cerebrospinal fluid ("CSF") pharmacokinetic characteristics of two forms of human chorionic gonadotropin ("hCG"): Pregnyl® and Ovitrelle®. Two separate groups, each with six older male human subjects, were administered a single dose of either form of the drug at 10,000 IU intramuscularly ("IM"), and then followed over a 36-hour period. No significant difference was observed when plasma levels of hCG were measured for either preparation of hCG (Peak plasma concentration: 316÷±53 versus 270÷±60 at 12 hours, 311÷±38 versus 321÷±60 IU/L at 24 hours; AUC: 10053÷±1268 versus 8793÷±1768, Pregnyl® and Ovitrelle®, mean ÷± SD, respectively). Additionally, both forms of circulating hCG distributed to the central nervous system ("CNS") as manifest by an increased number of subjects whose CSF samples showed detectable levels of hCG in their CSF over a 36-hour period. Similarly, there was no significant difference between the two forms when distribution to the CSF was compared at 36 hours (2.0 and 1.2 IU/L; range 1.9-2.1 and 1-1.4 IU/L for Pregnyl® and Ovitrelle®, respectively). This preliminary study in normal human volunteers suggested that the two forms of hCG tested, Pregnyl® and Ovitrelle®, when administered IM, distribute in a similar fashion into the circulation and CSF. Consequently, SCT concluded that these two drugs likely demonstrate bioequivalent pharmacokinetics with respect to the CSF. Stem Cell Therapeutics Corp.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009